Retinoic-acid-induced apoptosis in leukemia cells

Trends Mol Med. 2004 Oct;10(10):508-15. doi: 10.1016/j.molmed.2004.08.006.

Abstract

Retinoic acid (RA) cures more than 75% of patients with acute promyelocytic leukemia (APL). Here, we review the various anti-cancer activities of retinoids and rexinoids, alone and in combination with other drugs, with emphasis on the RA-dependent induction of a cancer-cell-selective apoptosis signaling pathway to which multiple anti-cancer signals converge. These findings identify the TRAIL (tumor-necrosis-factor-related apoptosis-inducing ligand) pathway as a central cell-autonomous anti-cancer weapon that can act independently of the immune system.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Apoptosis / drug effects*
  • Apoptosis Regulatory Proteins
  • Epigenesis, Genetic
  • Humans
  • Leukemia, Promyelocytic, Acute / drug therapy*
  • Membrane Glycoproteins / metabolism
  • Models, Molecular
  • Receptors, Retinoic Acid / metabolism
  • Retinoids / pharmacology*
  • Retinoids / therapeutic use
  • TNF-Related Apoptosis-Inducing Ligand
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Apoptosis Regulatory Proteins
  • Membrane Glycoproteins
  • Receptors, Retinoic Acid
  • Retinoids
  • TNF-Related Apoptosis-Inducing Ligand
  • TNFSF10 protein, human
  • Tumor Necrosis Factor-alpha